title: Treatment of childhood renal cell carcinoma with lymph node metastasis: two cases and a review of literature.
abstract: Standard treatment for renal cell carcinoma (RCC) is radical nephrectomy with lymph node dissection. Stages I and II have encouraging prognoses, but Stage III with regional lymph node metastasis can be unfavorable. Adjuvant therapy for pediatric patients with advanced RCC with lymph node involvement or metastatic lesion has not been defined. Advanced pediatric RCC is reported in two patients (boys, aged 6 and 9 years: Stage IIIs, Robson; Stage III and IV, pTNM classification) treated by nephrectomy and lymph node dissection followed by postoperative interferon-alpha (IFN), that can be used as an adjuvant therapy with side effects such as fever, bone marrow suppression, or decreased liver function. One is doing well for 7 years, another is suffered from lung metastases at 3 years after surgery. Although immunotherapy is expected to improve survival in pediatric patients with advanced RCC, surgical resection of renal and metastatic tumors remains the standard treatment.
authors.affiliation: Department of Pediatric Surgery, Niigata University School of Medicine, Niigata, Japan. uchii@med.niigata-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Uchiyama
authors.forename: M
authors.initials: M
authors.lastname: Iwafuchi
authors.forename: M
authors.initials: M
authors.lastname: Yagi
authors.forename: Y
authors.initials: Y
authors.lastname: Iinuma
authors.forename: M
authors.initials: M
authors.lastname: Ohtaki
authors.forename: Y
authors.initials: Y
authors.lastname: Tomita
authors.forename: M
authors.initials: M
authors.lastname: Hirota
authors.forename: S
authors.initials: S
authors.lastname: Kataoka
authors.forename: K
authors.initials: K
authors.lastname: Asami
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D002648:Child; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D009392:Nephrectomy
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha